rjac/clinicaltrials.gov-summary_and_eligibility huggingface dataset:
The Effect of the Emotional Freedom Technique on Perceived Pain, Situational Anxiety, Cortisol and Satisfaction Levels in Mammography Screening.
Status: Not yet recruiting

This study was planned to determine the effect of Emotional Freedom Technique on perceived pain level, situational anxiety, salivary cortisol and satisfaction level during mammography screening.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Having a first mammography screening Knowing how to read and write, Having entered menopause (at least 1 year has passed since the last menstruation)  Exclusion Criteria:  Having any cognitive or hearing-related problems, Having used analgesic medication before the procedure, Not having chronic diseases (insulin resistance, hypertension, obesity) (as saliva may affect cortisol level), Having a psychiatrically diagnosed disease (Schizophrenia, bipolar disorder) Having epilepsy (since it is contraindicated for EFT applications), Presence of oral diseases, inflammation or lesions (as saliva may affect cortisol level), Having eaten, drank, chewed gum or brushed teeth 30 minutes before. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 40 Years - MaximumAge: 50 Years - StdAgeList: Adult
A mHealth System for Patients With POTS
Status: Recruiting

Postural Orthostatic Tachycardia Syndrome (POTS) affects approximately 500,000 - 3 million Americans. This number will only increase due to the large number of patients experiencing POTS due to "long COVID." POTS patients experience several symptoms, including tachycardia, palpitations, dizziness, and pre-syncope or syncope, among others. POTS can be very debilitating and not only affect patients physically but also emotionally and financially. It takes an average of four years and seven doctors for POTS patients to achieve a diagnosis and it is often a frustrating and negative experience fraught with misdiagnoses, stigma, and depression and anxiety. Recent research demonstrates that mHealth technology may be one way that POTS patients can improve their experience in the healthcare system by providing objective data to their healthcare providers. Patients may also better take care of themselves through symptom monitoring and instant patient education via mHealth technology. The two study aims are: 1) Developing a mHealth app to improve the delay to diagnosis and the quality of life of POTS patients; and 2) Evaluate the usability and feasibility of the mHealth app and study design. To achieve these aims, researchers in this study will work with a programmer and leaders from the mHealth Application Modernization and Mobilization Alliance (MAMMA) and stakeholders (patients, caregivers, and providers) to co-design a mHealth app for POTS patients, including key educational components guided by the IDEA model, an instructional risk communication approach. A group of diagnosis-seeking POTS (n=20) patients will pilot test the app and provide feedback for improvement as well as evaluate its usability. Results from this study will allow researchers to acquire necessary data to apply for external funding to conduct a larger clinical trial to evaluate its influence on health outcomes, such as patient experience during visits with physicians, perceived stigma, and time to diagnosis.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  patients who have not received a POTS diagnosis from a physician must have experienced at least two symptoms of POTS within the past three months (one symptom must include dizziness or pre-syncope upon standing) must have a clinic visit scheduled within 2-4 months post-recruitment  Exclusion Criteria:  have been diagnosed with POTS already is not at least 18 years of age is not experiencing at least two symptoms of POTS within the past three months, including dizziness or pre-syncope upon standing. does not have a clinic visit scheduled within 4 months post-enrollment is taking a beta blocker. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
To Wipe or Not To Wipe?: That Is The Question
Status: Not yet recruiting

The primary aim of this randomized control trial is to characterize whether a mid-stream clean catch sample using a cleansing wipe in the setting of symptomatic UTI in a female patient is associated with a lower rate of contamination. We hypothesize that using a perineal cleansing wipe at the time of a midstream urine sample will decrease rates of contamination for female patients with a symptomatic UTI.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  adult female patients >18 who present to the urology clinic at IRL or 3RC with a symptomatic UTI: symptoms include urgency, frequency, urgency urinary incontinence increased from baseline symptoms, dysuria, fevers, flank pain, suprapubic pain/pressure, low back pain, cloudy urine, malodorous urine  Exclusion Criteria:  patients who are asymptomatic, have an indwelling catheter, SPT, stent, nephrostomy tube, perform CIC, are on daily antibiotic prophylaxis, or already on existing antibiotics - HealthyVolunteers: No - Gender: Female - MinimumAge: 18 Years - MaximumAge: 100 Years - StdAgeList: Adult, Older Adult
The Krill Ageing Muscle Mechanisms (KAMM) Study
Status: Not yet recruiting

This study aims to determine the mechanisms via which krill oil supplementation increases muscle strength and whether this translates to improvements in gait and functional characteristics in older adults. The studies we will carry out will establish, in healthy older adults, the effects of 6 months of supplementation with krill oil

Objective 1) Muscle structure and function Hypothesis: Krill oil supplementation will increase muscle size and strength alongside positive changes in muscle architecture (pennation angle and fascicle length).

Objective 2) Neuromuscular control and central nervous system (CNS) function Hypothesis: Krill oil supplementation will improve Neuromuscular Junction (NMJ) transmission stability and increase central drive and intramuscular coherence, as a measure of muscle synergy.

Objective 3) Gait and functional characteristics Hypothesis: Krill oil supplementation will improve gait and functional characteristics.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  body mass index (BMI) </= 30 kg/m2 Age >/= 65 years Capacity to consent Living within the Glasgow area  Exclusion Criteria:  Diabetes mellitus Severe cardiovascular disease Seizure disorders Uncontrolled hypertension (>150/90mmHg) Active cancer or cancer that has been in remission <5 years Participation in any resistance exercise training within the last 6 months Impairments which may limit ability to perform assessments of muscle function Dementia Fish/shellfish allergy Taking medication known to affect muscle (e.g. steroids, Selective serotonin reuptake inhibitors) or anticoagulants (e.g. warfarin) Taking omega-3 supplements in the last 3 months Regularly consuming 1 or more portions of oily fish per week Not able to understand English - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 65 Years - MaximumAge: 90 Years - StdAgeList: Older Adult
Effect of DASH on HF Outcomes Heart Failure Status in Older Adults (DASH HF)
Status: Not yet recruiting

The purpose of this study is to examine the effect of the Dietary Approaches to Stop Hypertension (DASH) diet has on heart failure status in older adults. This study is important because it may provide a low-cost strategy to help reduce hospitalizations and deaths for heart failure patients. Participants will be adults age 65 and older with heart failure. They will have 4 study visits, each lasting about 2 hours, and will be in the study for 12 weeks. They will also be asked about their dietary consumption 6 times, each time lasting about 45 minutes. All in-person study visits will take place in the Emory GCRC. Participants will have physical exams, body measurements, blood tests, urinalysis, chart review, and answer surveys. They will be randomized to eat only the DASH diet provided to them for 4 weeks either at the beginning or end of their participation in the study. Participants will be recruited from heart failure patients at Emory University Hospital, Emory University Hospital Midtown, and Emory Outpatient Advanced Heart Failure Therapy Center. The total enrollment planned under Emory's oversight, accounting for screen failures and withdrawals, will be n=38 participants. The study team will obtain informed consent prior to the first study visit either in person, or, alternatively, over the phone, if requested by participants. Specimens and data obtained in this study will not be banked for future use.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  65+ years of age Heart failure diagnosis and symptoms, as outlined by the 2021 European Society of Cardiology diagnostic guidelines Residence within 50 miles of Emory University Have undergone hemodynamic monitoring device implantation (CardioMEMS, Abbott) Have received optimized HF therapy for 3+ months post CardioMEMS implantation  Exclusion Criteria:  Heart failure-related hospitalization or heart failure medication changes within 1 month Renal disease stages IV-V Expected survival < 12 months Dementia or Alzheimer's disease Limited English literacy and communication skills - HealthyVolunteers: No - Gender: All - MinimumAge: 65 Years - MaximumAge: 110 Years - StdAgeList: Older Adult
Effect of Continuing Versus Holding Metformin During Hospitalizations.
Status: Not yet recruiting

A randomized study of continuing versus holding metformin during hospitalizations to internal medicine services to determine the effects on glucose control, acidosis, abdominal symptoms, length of stay, and mortality.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Adult (18+ years of age) Admitted to an internal medicine service. On Metformin prior to admission.  Exclusion Criteria:  Inability to take oral medications eGFR < 30 ml/min/1.73 m2 Dialysis Current Acidosis (pH < 7.35) including diabetic ketoacidosis Child-Turcotte-Pugh class C hepatic cirrhosis Acute Decompensated Heart Failure Cognitively impaired and/or unable to consent Lack of or unwillingness to share contact information Pregnant women - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 110 Years - StdAgeList: Adult, Older Adult
Biomarkers for Peripheral Circadian Clocks in Humans
Status: Recruiting

The purpose of this project is to improve our understanding of peripheral circadian rhythms in humans. Circadian clocks are present in most tissues of the body with importance for optimal physiological function, health, and behavior. This project will utilize simulated jetlag protocols to systematically test novel hypotheses about the regulation of peripheral circadian rhythms in humans. Specifically, we will examine how changes in the time of when we are exposed to light and the timing of when we eat impacts proteins in the blood and saliva that represent rhythms from clocks in the brain (e.g., rhythms of the hormones melatonin and cortisol coordinated by the brain) and rhythms from clocks in body tissues (e.g., proteins made by immune and bone cells, and cells in the stomach and liver). We also aim to discover new blood-based biomarkers of peripheral rhythms in humans. We anticipate our findings will be the first step in developing novel circadian based treatments for aligning peripheral clocks under conditions such as jetlag, and for developing novel circadian biomarkers that will advance our scientific understanding of circadian rhythms.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  1) 17-35 years old 2) English speaking 3) Healthy 5) Altitude history: Currently residing at Denver altitude or higher  Exclusion Criteria:  1. Any medical, psychiatric, or sleep disorder. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 17 Years - MaximumAge: 35 Years - StdAgeList: Child, Adult
Adaptive DBS to Offset STN Dysregulation During Exercise in PD
Status: Not yet recruiting

The investigators conduct a prospective study to evaluate the effects of exercise on Parkinson's Disease brain biomarkers detected with the PerceptTM PC neurostimulator.

Eligibility:
- EligibilityCriteria: Inclusion Criteria: Persons with PD, who have a Medtronic DBS implant with a Percept IPG.  -  Exclusion Criteria: Persons not meeting the above listed age and implant criteria, who are not able to complete the study exercise, or not able to comprehend and consent to study participation.  - - HealthyVolunteers: No - Gender: All - MinimumAge: 20 Years - MaximumAge: 70 Years - StdAgeList: Adult, Older Adult - StudyPopulation: Persons with PD, who have a Medtronic DBS implant with a Percept IPG. - SamplingMethod: Probability Sample
Patient-centered Information on Permanent Contraception
Status: Not yet recruiting

The goal of this study is to understand whether providing information to women with a strong desire to avoid future pregnancy about how tubal sterilization compares to long-acting reversible contraceptives improves perceived access to available contraceptives.

Participants will:

Complete a baseline survey
Receive access to web-based educational resources
Complete a brief follow up survey immediately after exploring these web-based resources
Complete a follow-up survey 3 months after enrolling

The investigators will compare outcomes among participants provided with access to a new website (intervention) summarizing recent patient-centered outcomes research (PCOR) comparing interval laparoscopic tubal sterilization and long-acting reversible contraception (LARC) to control participants provided with access to the existing Planned Parenthood website on tubal sterilization.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Self-reported fertility Have a strong desire to avoid future pregnancy Speak English or Spanish  Exclusion Criteria:  Current pregnancy The inability to speak English or Spanish Prior tubal sterilization or Essure procedure Menopause Infertility Hysterectomy - HealthyVolunteers: Accepts Healthy Volunteers - Gender: Female - MinimumAge: 21 Years - MaximumAge: 45 Years - StdAgeList: Adult
The Effect of a Combined Aerobic and Resistance Exercise (CARE) Training Programme on Cardiometabolic Outcomes in Individuals With Chronic Spinal Cord Injury: A Randomised Controlled Trial
Status: Not yet recruiting

The goal of this study is to investigate the effectiveness of an 8-week dietary energy restriction with exercise or dietary energy restriction alone on the cardiometabolic health outcomes of individuals with chronic spinal cord injury. This study is a randomised controlled trial conducted at a single centre, consisting of two parallel arms. The main questions it aims to answer are:

the effectiveness of an 8-week dietary energy restriction with exercise or dietary energy restriction alone on cardiometabolic disease biomarker outcomes in individuals with chronic SCI
the effectiveness of an 8-week dietary energy restriction with exercise or dietary energy restriction alone on fitness and health outcomes.

Twenty-one participants will be randomly assigned in a 2:1 allocation ratio. The participants will be assigned to either the dietary energy restriction and exercise group (D+E) group, which combines dietary energy restriction and exercise intervention, or the dietary energy restriction group (D) group, which just undergoes dietary energy restriction using sealed envelopes.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  The inclusion criteria for participation in this study are that patients have a chronic SCI that occurred at least one year before, an age range between 18 and 65 years, and sufficient upper limb function to engage in the exercise intervention. Participants must self-report that they use a wheelchair for the majority of their waking hours, namely 75% of their day, and have continually maintained a stable weight within a range of ± 3 kg over the duration of the previous three months.  Exclusion Criteria:  The study will exclude participants who have provided information about their medical conditions, such as unresolved pressure sores, urinary tract infections, active medical conditions that may be a contraindication to exercise testing (ACSM Exercise Testing Guidelines), or current musculoskeletal symptoms of the upper extremities. Individuals who have self-reported the use of medication for type 2 diabetes or pharmaceuticals that influence glucose metabolism will be excluded from involvement in the research. - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 65 Years - StdAgeList: Adult, Older Adult
SiFi vs FNB Local Anesthesia for Hip Fracture Surgeries
Status: Not yet recruiting

The goal of this clinical trial is to compare two commonly used local/regional anesthesia techniques in adults patients undergoing hip fracture surgery. The main question[s] it aims to answer are: • the impact of both interventions on patient level of pain. • impact on postoperative analgesics administered Participants will be randomly assigned to one of two local/regional anesthesia techniques, either femoral nerve block (FNB) or suprainguinal fascia iliaca block (SiFi). Both techniques are the usual practice at the hospital, and we are NOT aiming to experiment on new anesthesia technique in this study.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Age 18 or greater Having hip fracture surgery at the University of Alberta Hospital Suitable for multimodal analgesia including a peripheral nerve block  Exclusion Criteria:  Contraindication to a nerve block technique Refuses consent for a nerve block technique - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
Status: Not yet recruiting

Pemetrexed is one of the first-line chemotherapeutic agents for non-squamous non-small cell lung cancer (NSCLC). Since 2017, intrathecal pemetrexed has shown good efficacy for patients with leptomeningeal metastases from NSCLC. It has been recommended as the preferred drug for intrathecal chemotherapy by the Chinese Society of Clinical Oncology (CSCO) guidelines. Tyrosine kinase inhibitors (TKIs) play a promising role in treating non-small cell lung cancer patients with epidermal growth factor receptor (EGFR) mutations. An international multi-center clinical study published in 2019 confirmed that double dose of osimertinib showed significant improvement in leptomeningeal metastases from NSCLC with EGFR exon 19 deletion or exon 21 L858R/T790M mutation. It makes TKIs the mainstay of treatment for patients with EGFR-mutant NSCLC with leptomeningeal metastases. However, the choice of treatment after resistance to targeted therapy is a hot topic in clinical practice, with 78% of patients in the study above who responded to double-dose osimertinib still showing progression at the time of follow-up. The purpose of this study was to observe the safety and efficacy of intrathecal pemetrexed for leptomeningeal metastasis from lung adenocarcinoma that progressed after a double dose of a third-generation TKI such as osimertinib.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Male or female aged between 18 and 75 years. Histologically or cytologically confirmed diagnosis of NSCLC with single activating EGFR mutations (L858R or Exon19Del). Confirmed diagnosis of leptomeningeal metastasis according to ESMO/ EANO guidelines. Progression after previous double doses of third-generation TKIs such as Osimertinib. Normal liver and kidney function; WBC≥4000/mm3, Plt≥100000/mm3. No history of severe nervous system disease. No severe dyscrasia.  Exclusion Criteria:  Any evidence of nervous system failure, including severe encephalopathy, grade 3 or 4 leukoencephalopathy on imaging, and Glasgow Coma Score less than 11. Any evidence of extensive and lethal progressive systemic diseases without effective treatment. Patients with poor compliance or other reasons that were unsuitable for this study - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - MaximumAge: 75 Years - StdAgeList: Adult, Older Adult
Abdominal Neuroblastoma Laparoscopic Surgery Risk Factors Stratification
Status: Recruiting

Surgery plays significant role in treatment of neurogenic tumors, both for benign ganglioneuroma and for high risk neuroblastoma. The world literature has accumulated large experience in laparoscopic surgery for abdominal neuroblastoma. The presence of IDRF (image-defined risk factors) and tumor size (>4-7 cm) are considered as common contraindications for minimally invasive surgery in neuroblastoma. However, the recent studies have shown that presence of IDRF is not an absolute contraindication for laparoscopic surgery. This open-label, nonrandomized, observational, phase III evaluates role and weight of different surgical risk factors (including IDRF, tumor size, tumor localization, tumor volume/patient height ratio, previous open surgical procedures, previous chemotherapy etc.) in the laparoscopic neuroblastoma resections. The aim of this study is to create novel risk factors scoring system for laparoscopic surgery in abdominal neuroblastoma.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  Patients with neurogenic tumors meeting the criteria of groups I-III:  Group I  low or moderate risk group according to pilot difficulty scoring system (less than 5 points, see supplementary material); no IDRF;  Group II:  low or moderate risk group according to pilot difficulty scoring system (less than 5 points); patients with any number of IDRFs and without central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more.  Group III:  2 and more IDRF + central tumor location and/or tumor extension across the midline; 2 and more IDRF + tumor volume (cm3)/patient height (m) ratio = 28 or more; 2 and more IDRF + 2 and more other risk factors according to pilot difficulty scoring system; 1 IDRF + tumor extension across the midline + tumor volume (cm3)/patient height (m) ratio = 28 or more. Age from 0 to 18 years. Preoperative imaging (abdominal contrast-enhanced computed tomography (CT), performed no later than 14 days before the planned surgery). Indications for surgery based on the decision of multidisciplinary experts board in centers- participants. Written voluntary informed consent of the patient and / or his legal representative.  Exclusion Criteria:  3 and more IDRF + central tumor location and/or tumor extension across the midline and/or tumor volume (cm3)/patient height (m) ratio = 28 or more. Severe concomitant pathology, increasing anesthesiologic and surgical risks, via the desicion of the research physician or conclusion by multidisciplinary team in centers- participants. Tumor volume does not technically allow to provide minimally-invasive surgery, based on the conclusion of multidisciplinary experts board team in centers- participants.  Therapy strategy: observation  - - Gender: All - MinimumAge: 1 Day - MaximumAge: 18 Years - StdAgeList: Child, Adult - StudyPopulation: Patients with abdominal neurogenic tumors in 0-18 years of age - SamplingMethod: Non-Probability Sample
The Chit-Chat Educational Intervention to Promote Advance Care Planning in the Community
Status: Not yet recruiting

The purpose of this study is to estimate the effect size of the Chit-Chat intervention on ACP engagement among family members of older adults with multi-morbidity.

Eligibility:
- EligibilityCriteria: Inclusion Criteria:  age 18 or above; a family member of a relative who aged 60 or above and lives with at least two severe chronic diseases such as cancer, dementia, lung, heart, liver, and renal disease. they perceived themselves will take part in taking care of their relatives in the near future; able to read and communicate in Cantonese.  Exclusion Criteria:  they are cognitively incompetence (Mini-Mental State Examination (MMSE) < 23); their relatives have been referred to palliative care service before the study. - HealthyVolunteers: Accepts Healthy Volunteers - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult